Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Sana Biotechnology Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.35, while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| QYLD | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $5.92 |
52-Week Low | $16.70 | $2.68 |
Market Cap | — | $1.03B |
Enterprise Value | — | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.37, showing minimal daily movement with a 0.05% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Recent dividend payments of $0.18-0.19 per share continue its income-focused strategy, but news coverage highlights concerns about long-term principal erosion compared to Nasdaq-100 index performance.
The covered-call strategy provides consistent monthly income but sacrifices upside potential during market rallies. While the 12% yield attracts income investors, long-term performance has significantly lagged the underlying index. Current technical strength suggests near-term stability, but structural limitations pose challenges for capital appreciation.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
